building a

solid tgct

care plan

When it comes to living with tenosynovial giant cell tumor (TGCT), you shouldn't have to endure the "bad days" alone. By partnering with the right care team, you can consider a range of treatment options for TGCT.1

Partnering with
your care team

You play a key role in developing a treatment plan that’s right for you. Share your treatment priorities—such as wanting to shrink your tumor or avoid worsening symptoms—and ask any questions you have about treatment options.

Some key questions:

  • What are my treatment options?
  • How well does the treatment remove or shrink TGCT? 
  • Will treatment reduce pain and stiffness?
  • Does treatment increase range of motion?
  • What are the potential risks and/or side effects 
of treatment?
  • How will treatment fit into my daily life and activities?

Some care teams use MRI to monitor TGCT. MRIs can help to show how you are responding to surgery or prescription medications before new symptoms develop or worsen.1

Understanding YOUR options

Surgery is often the primary treatment for TGCT, but it isn't right for everyone. Depending on how TGCT is affecting you, your options may also include closely monitoring symptoms over time (active surveillance) or using prescription medicines. The potential benefits of any management strategy should be weighed against potential side effects or complications. Together, you and your care team can find a treatment plan that works for you.1

ACTIVE SURVEILLANCE

Pros1

  • Preferred approach for most people without symptoms
  • Avoids surgery, medication, and potential side effects

Cons1,2

  • Does not actively shrink the tumor
  • Not appropriate for people who may experience life-threatening tumor growth or permanent joint damage

Surgery

Pros3,4

  • Reduces the size of the tumor and may remove it completely, which helps with symptoms
  • It’s possible that a single surgery will be all you need to remove the tumor

Cons5,6

  • Recovery can be long
  • Chance of recurrence is about 72% with diffuse TGCT and about 34% with localized TGCT

Prescription Medicines

Pros6

  • Some medicines target and block CSF-1, a main cause of tumor growth
  • Can help with symptoms

Cons7-9

  • Tumors don’t always shrink
  • The medicine needs to be taken regularly over the long term

Things are changing in TGCT

Stay up to date on the latest developments.

If you need more information about treatment options or have any questions, talk to your care team.

SIGN UP FOR MORE INFORMATION ON TGCT MANAGEMENT

SIGN UP FOR MORE INFORMATION ON TGCT MANAGEMENT

To learn about the latest insights on TGCT management and support to help you find the right treatment plan, sign up now. 

SIGN UP

REFERENCES

1. Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. Cancer Treat Rev. 2023;112:102491. doi:10.1016/j.ctrv.2022.102491. 2. National Cancer Institute. Active surveillance. Accessed May 28, 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/active-surveillance. 3. Gelhorn HL, Tong S, McQuarrie K, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther. 2016;38(4):778-793. doi:10.1016/j.clinthera.2016.03.008. 4. TGCT Support. Recovery. Updated 2022. Accessed May 12, 2025. https://www.tgctsupport.org/recovery.html. 5. Stern S, McKenzie PF, Bernthal N, et al. Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. Future Oncol. 2025;21(12):1501-1510. doi:10.1080/14796694.2025.2488635. 6. Romvimza. Prescribing information. Deciphera Pharmaceuticals, LLC. 7. Turalio. Prescribing information. Daiichi Sankyo, Inc. 8. Aykan NF, Özatlı T. Objective response rate assessment in oncology: current situation and future expectations. World J Clin Oncol. 2020;11(2):53-73. doi:10.5306/wjco.v11.i2.53

YOU ARE NOW LEAVING TGCTWRECKS.COM

By clicking "Continue" below, you will be taken away from tgctwrecks.com to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit. You are solely responsible for your interactions with such websites.

CONTINUE TO SITE
RETURN TO TGCTWRECKS.COM
Divider desktop
Divider mobile

© 2026 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

SpringWorks Therapeutics, Inc. and EMD Serono, Inc. are Healthcare companies of Merck KGaA, Darmstadt, Germany.

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Terms & Conditions and Privacy Policy.

US-NONOTGCT-00008 05/26